東陽光藥(01558.HK)年度純利跌56.25%至8.39億元
格隆匯 3 月 19日丨東陽光藥(01558.HK)公佈年度業績，截至2020年12月31日止年度，公司營業額為人民幣23.48億元，較去年減少62.27%；税息、折舊及攤銷前溢利為人民幣13.77億元，較去年減少46.19%；公司權益股東應占溢利及全面收益總額(不考慮可轉換債券影響)為人民幣5.90億元，較去年減少71.83%；公司權益股東應占溢利及全面收益總額(考慮可轉換債券影響)為人民幣8.39億元，較去年減少56.25%。每股基本及攤薄盈利分別為人民幣0.95元和人民幣0.53元。
2020年，集團營業額為人民幣23.48億元，較2019年同比減少62.27%，核心產品可威的銷售額為人民幣20.69億元，較2019年同期減少65.13%。同時，可威顆粒、可威膠囊、爾同舒、歐美寧及奧美沙坦酯片為集團的核心產品，佔總營業額比例分別為48.88%、39.22%、4.02%、1.17%及1.16%。
2020年受新型冠狀病毒肺炎疫情影響，中國國內人口流動性降低，醫院的診療活動數量、處方量及藥品銷量也隨之下降。集團核心產品可威為主要用於等級醫院銷售的處方藥，其銷售量亦受新型冠狀病毒肺炎疫情影響而下降。
雖受新冠狀病毒疫情影響，報吿期內業績有較大程度下降，但報吿期內在研產品進展順利，多個產品取得生產批件，亦有多個產品遞交新藥上市申請並獲受理。截至公吿日期，公司擁有自主知識產權的磷酸依米他韋膠囊獲批准上市，磷酸依米他韋膠囊是公司擁有自主知識產權的I類創新藥，屬於口服直接抗丙肝病毒藥物。截至公吿日期，公司自主研究及開發之產品重組人胰島素注射液，是公司首個獲批上市的生物製品藥物。另外，甘精胰島素注射液、門冬胰島素注射液及門冬胰島素30注射液已遞交境內生產註冊並獲受理；多個仿製藥品種獲得上市批件。
截至公吿日期，於2018年自廣東東陽光藥業收購的六款仿製藥組合已全部取得相應生產批件，報吿期整體銷售收入為人民幣8732萬元。集團於2019年2月自廣東東陽光藥業收購二十七款仿製藥組合，廣東東陽光藥業已全部向藥監局提交上市許可申請，其中，替格瑞洛片、瑞舒伐他汀鈣片、恩替卡韋片、奧氮平片、奧氮平口崩片、西格列汀片、西格列汀二甲雙胍片、利格列汀片、利格列汀二甲雙胍片、阿格列汀片及他達拉非片等已獲批准上市。待日後其他產品獲批上市將進一步豐富集團產品組合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
